Wolfgang Miesbach: Half of All Haemophilia Patients on Prophylaxis are Still Having Breakthrough Bleeds
Wolfgang Miesbach, shared post on LinkedIn about a recent article by Sheena Thakkar et al., published in Blood Coagulation and Fibrinolysis, adding:
“Half of all haemophilia patients on prophylaxis are still having breakthrough bleeds – and when they bleed, it’s the joint.
New real-world data from the Adelphi Haemophilia DSP (Thakkar et al., Blood Coagul Fibrinolysis 2026) – 739 men with haemophilia A, 131 with haemophilia B, six countries, physician-reported:
- Emicizumab was already the most-used treatment in HA (40%), EHL factor in HB (55%)
- Yet 48% (HA) and 54% (HB) had breakthrough bleeds since switching to their current prophylaxis
- Among those who bled, joint bleeds dominated in both: 53% and 57%
Haemophilia B was not the milder disease
Prophylaxis is not the same as protection. As long as the joint remains the target organ, ‘well controlled’ on paper can still mean progressive arthropathy in the clinic.
These data were collected in 2020/21 — before Efanesoctocog alfa, gene therapy, and the current generation of non-factor agents reached routine practice.”
Title: Describing the clinical outcomes and treatment landscape for male haemophilia A and B patients in a real-world setting across Europe and the United States
Authors: Sheena Thakkar, Lisa J. Wilcox, Valeria Merla, Anna Kane, Rabiyah Sahar, Chris Blazos, Sophie Lai, Ella Morton, Kieran Wynne-Cattanach, Nathan Ball.

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation